SCHEMBL24466980

SCHEMBL24466980

O=S(=O)(c1ccc(F)cc1)N1CCC(Oc2ncnc3ccsc23)CC1

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ LSS P48449 1/20 0.46
▸ TP53 P04637 1/20 0.46
▸ HTR2B P41595 1/20 0.43
▸ KMT2A Q03164 1/20 0.42
▸ PKM P14618 2/20 0.42
▸ MAPT P10636 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ GPR119 Q8TDV5 3/20 0.41
▸ CNR1 P21554 1/20 0.40
▸ CNR2 P34972 1/20 0.40
▸ NAMPT P43490 1/20 0.40
▸ FPR2 P25090 1/20 0.39
▸ PROKR1 Q8TCW9 1/20 0.39
▸ KDM4E B2RXH2 2/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ SCN1A P35498 1/20 0.39
▸ SCN8A Q9UQD0 1/20 0.39
▸ GAA P10253 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24466915 0.90 ALDH1A1 (0.47) TP53KMT2APKMMAPTSMN1; SMN2
SCHEMBL29714957 0.90 MAPT (0.42) MAPTSMN1; SMN2GPR119CNR1CNR2
SCHEMBL29808793 0.90 KMT2A (0.46) KMT2APKMMAPTSMN1; SMN2GPR119
SCHEMBL24466948 0.90 MAPT (0.42) MAPTSMN1; SMN2GPR119CNR1CNR2
SCHEMBL24467002 0.90 KMT2A (0.46) KMT2APKMMAPTSMN1; SMN2GPR119
SCHEMBL24467042 0.88 SMN1; SMN2 (0.54) TP53KMT2APKMSMN1; SMN2SCN1A
SCHEMBL29808613 0.88 SMN1; SMN2 (0.60) KMT2APKMMAPTSMN1; SMN2L3MBTL1
SCHEMBL24466985 0.88 SMN1; SMN2 (0.60) KMT2APKMMAPTSMN1; SMN2L3MBTL1
SCHEMBL24466951 0.84 PKM (0.44) KMT2APKMSMN1; SMN2GPR119FPR2
SCHEMBL29808682 0.84 PKM (0.44) KMT2APKMSMN1; SMN2GPR119FPR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220402935-A1 HETEROCYCLIC COMPOUND FIMECS, INC. (JP) 2022-12-22 — — US disclosed
EP-4006037-A1 HETEROCYCLIC COMPOUND Fimecs, Inc. (JP) 2022-06-01 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220402935-A1 HETEROCYCLIC COMPOUND IRAK1, IRAK2, IRAK4 LSS 3533/4885TP53 792/4885HTR2B 4627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback